Citations

Mayo Clinic

Showing 10 of 108376 citations.

Differentiation of uric acid versus non-uric acid kidney stones in the presence of iodine using dual-energy CT
Wang, Jia , Qu, Mingliang , Leng, Shuai , McCollough, Cynthia H.

SPIE Proceedings | March 17, 2010 | Volume: 7622 | Issue: No issue available | Pages: 76223O

10.1117/12.845046 Get It

Evaluation of dual-front active contour segmentation and metal shadow filling methods on metal artifact reduction in multi-slice helical CT
Yu, Lifeng , Guimarães, Luís , Li, Hua , Yu, Lifeng , Fletcher, Joel G. , McCollough, Cynthia H.

SPIE Proceedings | March 17, 2010 | Volume: 7622 | Issue: No issue available | Pages: 76222N

10.1117/12.844277 Get It

Establishing pharmacy operations in a new hospital while transferring existing operations to new ownership
Crumb, Deborah J.

American Journal of Health-System Pharmacy | March 17, 2010 | Volume: 67 | Issue: 7 | Pages: 566-571

10.2146/ajhp090358 | PMID 20237385 Get It

What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?
Sargent, Daniel J.

The Oncologist | March 17, 2010 | Volume: 15 | Issue: S1 | Pages: 19-23

10.1634/theoncologist.2010-s1-19 | PMID 20237213 Get It

Abstract The need to practice evidence-based medicine is the current prevailing paradigm within the medical community. Evidence to guide practice can and should come from a variety of sources, including clinical trials, observational studies, and meta-analyses of both or either. This paper discusses the relative strengths and weaknesses of data that arise from these various sources. The different types of evidence required to demonstrate “efficacy” versus “effectiveness,” a critical and often overlooked distinction, are discussed. In the genomic age, in which targeted therapies with or without specific biomarkers are emerging in cancer care, new approaches are necessary to generate the evidence required for decision making.
Conference Scene: The Great Debate: Genome-Wide Association Studies in Pharmacogenetics Research, Good or Bad?
Bailey, Kent R. , Cheng, Cheng

Pharmacogenomics | March 17, 2010 | Volume: 11 | Issue: 3 | Pages: 305-308

10.2217/pgs.10.6 | PMID 20235786 Get It

Conference Scene: Lessons Learned from the 5th Statistical Analysis Workshop of the Pharmacogenetics Research Network
Atkinson, Elizabeth J. , McDonnell, Shannon K. , Witte, John S. , Crawford, Dana C. , Fan, Yiping , Li, Lang , Rodin, Andréi S. , Speed, Terry, Yerges, Laura, Schaid, Daniel J. , Fridley, Brooke L. , Li, Dalin , Sadée, Wolfgang , Speed, Terry, Weiss, Scott T. , Yang, Jun J.J. , McDonnell, Shannon K

Pharmacogenomics | March 17, 2010 | Volume: 11 | Issue: 3 | Pages: 297-303

10.2217/pgs.10.5 | PMID 20235785 Get It

Safety of Contrast Agent Use During Stress Echocardiography in Patients With Elevated Right Ventricular Systolic Pressure
Abdelmoneim, Sahar S. , Bernier, Mathieu , Scott, Christopher G. , Dhoble, Abhijeet , Ness, Sue Ann C., Hagen, Mary E., Moir, Stuart , McCully, Robert B. , Pellikka, Patricia A. , Mulvagh, Sharon L. , Scott, Christopher , Pellikka, Patricia A

Circulation: Cardiovascular Imaging | March 17, 2010 | Volume: 3 | Issue: 3 | Pages: 240-248

10.1161/circimaging.109.895029 | PMID 20233859 Get It

Background— Microbubble safety concerns led to changes in product recommendations for patients with pulmonary hypertension. Noninvasive estimation of right ventricular systolic pressure (RVSP) is equivalent to pulmonary artery systolic pressure in the absence of pulmonary outflow obstruction. We analyzed the short- and long-term outcomes of patients who received microbubble contrast and those who did not during stress echocardiography (SE) according to resting RVSP. Methods and Results— From November 2003 to December 2007, 26 774 patients underwent SE. RVSP (mean, 32.6�9.6 mm Hg) was measured in 16 434 patients. Of these, 6164 (37.5%) received contrast for left ventricular opacification and 10 270 (62.5%) did not. Short-term (≤72 hours and ≤30 days) and long-term (4.3 years) end points were death and myocardial infarction. Analysis was done for rest RVSP cut-points ≥35, ≥50, and ≥60 mm Hg and tricuspid regurgitant velocities ≥2.7 ms −1 and ≥3.5 ms −1 . Adjusted Cox regression models were used. The contrast cohort comprised older patients (age, 67�12 versus 64�14 years; P <0.001), who were more likely to have positive SE results (35% versus 30%, P <0.001) compared with the noncontrast cohort. Using RVSP ≥50 mm Hg, there was no significant difference in short-term events between the contrast and noncontrast cohorts. For long-term events, there was no significant difference between both cohorts (adjusted hazard ratios [95% confidence intervals] for death, 1.10 [0.80 to 1.50], P =0.56; and myocardial infarction, 0.34 [0.11 to 1.03], P =0.06). Similar results were obtained at different RVSP and tricuspid regurgitant cut-points. Contrast agent–related adverse effects occurred in <1% of patients. Conclusion— RVSP had no impact on predisposition to adverse outcomes in patients undergoing contrast SE in the population studied.
Mitral Annular Dynamics in Myxomatous Valve Disease
Grewal, Jasmine , Suri, Rakesh M. , Mankad, Sunil , Schaff, Hartzell V. , Miller, Fletcher A., Tanaka, Akiko , Mahoney, Douglas W. , Enriquez‐Sarano, Maurice , Enriquez-Sarano, Maurice , Schaff, Hartzell

Circulation | March 16, 2010 | Volume: 121 | Issue: 12 | Pages: 1423-1431

10.1161/circulationaha.109.901181 | PMID 20231533 Get It

Background— Mitral annulus is a complex structure of poorly understood physiology. Full-volume real-time 3-dimensional transesophageal echocardiography offers a unique opportunity to completely image and quantify mitral annulus size and motion. Methods and Results— Real-time 3-dimensional transesophageal echocardiography of the mitral valve was acquired in 32 patients with myxomatous valve disease (MVD) and moderate to severe regurgitation, 15 normal control subjects, and 10 patients with ischemic mitral regurgitation of identical body surface area. Mitral annular dimensions (circumference, area, anteroposterior and intercommissural diameters, height, and ratio of height to intercommissural diameter ratio, which appraises annular saddle-shape depth) were measured throughout the cardiac cycle with dedicated quantification software. Compared with direct surgical measurement, 3-dimensional anterior annular dimension provided reliable measurements (mean difference, 0.1±0.1 mm; P =0.73; 95% confidence interval, ±4.4 mm). Annular dimensions were larger in MVD patients compared with control subjects in diastole (all P <0.05). Normal annulus displayed early-systolic anteroposterior ( P <0.001) and area ( P =0.04) contraction, increased height ( P <0.001), and deeper saddle shape (ratio of height to intercommissural diameter, 15±1% to 21±1%; P <0.001), whereas intercommissural diameter was unchanged ( P =0.30). In contrast, MVD showed early-systolic intercommissural dilatation ( P =0.02) and no area contraction ( P =0.99), height increase ( P =0.11), or saddle-shape deepening ( P =0.35). Late-systolic MVD annular saddle shape deepened but annular area excessively enlarged ( P <0.04) as a result of persistent intercommissural widening ( P <0.02). MVD annulus also contrasts with ischemic mitral regurgitation annulus, which, despite similar anteroposterior enlargement, is narrower and essentially adynamic. After MVD repair, the annulus remained dynamic without systolic saddle-shape accentuation ( P =0.30). Conclusions— Real-time 3-dimensional transesophageal echocardiography provides insights into normal, dynamic mitral annulus function with early-systolic area contraction and saddle-shape deepening contributing to mitral competency. MVD annulus is also dynamic but considerably different with loss of early-systolic area contraction and saddle-shape deepening despite similar magnitude of ventricular contraction, suggestive of ventricular-annular decoupling. Subsequent area enlargement may contribute to mitral incompetence. After mitral repair, MVD annulus remains dynamic without systolic saddle-shape accentuation. Thus, real-time 3-dimensional transesophageal echocardiography provides new insights that allow the refining of mitral pathophysiology concepts and repair strategies.
Src kinase regulates the integrity and function of the Golgi apparatus via activation of dynamin 2
Weller, Shaun G. , Capitani, Mirco, Cao, Hong , Micaroni, Massimo , Sallese, Michele , McNiven, Mark A. , Luini, Alberto

Proceedings of the National Academy of Sciences | March 15, 2010 | Volume: 107 | Issue: 13 | Pages: 5863-5868

10.1073/pnas.0915123107 | PMID 20231454 Get It

The size and integrity of the Golgi apparatus is maintained via a tightly controlled regulation of membrane traffic using a variety of different signaling and cytoskeletal proteins. We have recently observed that activation of c-Src has profound effects on Golgi structure, leading to dramatically vesiculated cisternae in a variety of cell types. As the large GTPase dynamin (Dyn2) has been implicated in Golgi vesiculation during secretion, we tested whether inhibiting Dyn2 activity by expression of a Dyn2K44A mutant or siRNA knockdown could attenuate active Src-induced Golgi fragmentation. Indeed, these perturbations attenuated fragmentation, and expression of a Dyn2Y(231/597)F mutant protein that cannot be phosphorylated by Src kinase had a similar effect . Finally, we find that Dyn2 is markedly phosphorylated during the transit of VSV-G protein through the TGN whereas expression of the Dyn2Y(231/597)F mutant significantly reduces exit of the nascent protein from this compartment. These findings demonstrate that activation of Dyn2 by Src kinase regulates Golgi integrity and vesiculation during the secretory process.
Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis
Dingli, David , Kumar, Shaji , Dispenzieri, Angela , Hayman, Suzanne R. , Lacy, Martha Q. , Gastineau, D A, Tan, Timothy Shao Ern , Buadi, Francis K. , Hogan, William J. , Gertz, Morie A. , Dispenzieri, Angela , Dingli, David

Neurology | March 15, 2010 | Volume: 74 | Issue: 11 | Pages: 913-918

10.1212/wnl.0b013e3181d55f4d | PMID 20231668 Get It